Clinical trial · Interventional
Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
A Phase II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Advanced Obstructing Endobronchial Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): drug cannot be prepared commercially
Summary
Brief summary (as posted)
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for advanced non-small cell lung cancer that blocks the air passages. PURPOSE: This phase II trial is studying how well photodynamic therapy using HPPH works in treating patients with advanced non-small cell lung cancer that blocks the air passages.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| endoscopic procedure | Procedure | — | UNRESOLVED |
| HPPH | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HPPH
- description
- Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.
- interventionNames
- Drug: HPPH
- Procedure: endoscopic procedure
Primary outcomes (1)
- measure
- Tumor Response
- timeFrame
- 6 months
Secondary outcomes (4)
- measure
- Palliation of Symptoms as Assessed by the Pulmonary Symptom Scale
- timeFrame
- 2 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Biopsy confirmed advanced obstructing endobronchial non-small cell lung cancer * May have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma histology * Ineligible for or refused surgical resection * Local endobronchial recurrence after prior surgical resection, radiotherapy, or chemotherapy allowed * No evidence of tumor encasement of major pulmonary vessels on CT scan of the chest PATIENT CHARACTERISTICS: * Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2 * WBC ≥ 4,000/mm³ * Platelet count ≥ 100,000/mm³ * Prothrombin time \< 1.5 times upper limit of normal (ULN) * Total bilirubin ≤ 2.0 mg/dL * Creatinine ≤ 2.0 mg/dL * Alkaline phosphatase (hepatic) ≤ 3 times ULN * SGOT ≤ 3 times ULN * No contraindications for bronchoscopy * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after the completion of study treatment * Patients with underlying lung disease must be judged (by the principal investigator) able to withstand mucous/debris formation at the site of treatment * Patients who cannot breathe due to complete upper airway obstruction and who need emergency treatment to open the airway are not eligible * No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds * No severe chronic obstructive pulmonary disease that, in the opinion of the investigator, would preclude multiple bronchoscopies * No partial central airway obstruction from mucous/debris formation * No high-grade upper airway obstruction of the trachea PRIOR CONCURRENT THERAPY: * Any type of prior therapy (e.g., chemotherapy or radiotherapy) for lung cancer allowed * At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy
References
Publications (0)
Data not yet available